The proposed Mayo Alzheimer's Disease Research Center (ADRC) will build upon the experience of the previously funded Mayo Alzheimer's Disease Center (P30) and the new faculty at Mayo Jacksonville, FL and the Mayo Scottsdale, AZ to address research questions in aging and Alzheimer's disease (AD). The ADRC will consist of five cores: Administrative Core, Clinical and Research Support Core, Neuropathology and Genetics Core, Neuroimaging Core and Education and Information Transfer Core, and two projects: Project 1: """"""""Cytoskeletal Pathology in the Neurodegeneration of AD,""""""""Project """"""""The contribution of Leukoaraisosis to Cognitive Impairment in Aging and Alzheimer's Disease."""""""" The Center will address several scientific themes including neuroepidemiology of dementia and AD, the boundary between normal aging and AD, and predictors of cognitive impairment in asymptomatic persons. New faculty appointments in Mayo Jacksonville in the basic science of amyloid processing, tau, genetics and antibody development will complement the clinical and epidemiology expertise in the remainder of the Center. Investigators in Scottsdale will add functional imaging studies in at-risk subjects to pursue the scientific themes of the Center. The proposed ADRC will extend the productivity of the existing Alzheimer's Disease Center and develop new insights into aging and AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
3P50AG016574-04S2
Application #
6667008
Study Section
Special Emphasis Panel (ZAG1 (J5))
Program Officer
Phelps, Creighton H
Project Start
1999-05-01
Project End
2004-04-30
Budget Start
2002-09-30
Budget End
2003-04-30
Support Year
4
Fiscal Year
2002
Total Cost
$52,378
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kantarci, Kejal; Tosakulwong, Nirubol; Lesnick, Timothy G et al. (2018) Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. Neurology 90:e1404-e1412
Ogaki, Kotaro; Martens, Yuka A; Heckman, Michael G et al. (2018) Multiple system atrophy and apolipoprotein E. Mov Disord 33:647-650
Utianski, Rene L; Whitwell, Jennifer L; Schwarz, Christopher G et al. (2018) Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. Cortex 99:358-374
Johnson, Derek R; Hunt, Christopher H; Nathan, Mark A et al. (2018) Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. J Neurooncol 136:373-378
Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17
Graff-Radford, Jonathan; Raman, Mekala R; Rabinstein, Alejandro A et al. (2018) Association Between Microinfarcts and Blood Pressure Trajectories. JAMA Neurol 75:212-218
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Wilmoth, Kristin; LoBue, Christian; Clem, Matthew A et al. (2018) Consistency of traumatic brain injury reporting in older adults with and without cognitive impairment. Clin Neuropsychol 32:524-529
Jones, David T; Knopman, David S; Graff-Radford, Jonathan et al. (2018) In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology 90:e947-e954
Wennberg, Alexandra M V; Hagen, Clinton E; Edwards, Kelly et al. (2018) Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. Int J Geriatr Psychiatry 33:1114-1120

Showing the most recent 10 out of 1014 publications